Issue: July 2012
July 01, 2012
1 min read
Save
ADVANCE III
Issue: July 2012
Primary endpoint was to demonstrate a 20% reduction of ventricular therapies delivered for treating spontaneous arrhythmia episodes with a fast cycle length.
